Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 10 of 15

TitleReference numberPublishedLast updated
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Regorafenib for previously treated metastatic colorectal cancerTA866
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancerTA668
Cetuximab and panitumumab for previously untreated metastatic colorectal cancerTA439
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)TA240
Trifluridine–tipiracil for previously treated metastatic colorectal cancerTA405
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)TA334
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapyTA307

Results per page

  1. 10
  2. 25
  3. 50
  4. All